In this trial, we aimed to assess the effects of dapagliflozin, one of the SGLT2 inhibitors, on glucose fluctuation in patients with type 2 diabetes mellitus on insulin using a prospective, randomized parallel-group comparison study design. Here, SLC5A2 is linked to type 2 diabetes mellitus.